Ketamine plus real-time fMRI neurofeedback for alcohol use disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized Phase 2 trial gives adults with alcohol use disorder either ketamine or placebo together with real-time fMRI neurofeedback or a sham procedure to measure effects on drinking and brain chemistry. Investigators will compare intervention groups and track mean alcohol use per day and heavy drinking days one month after the last treatment. The study will measure changes in glutamatergic neurotransmission in the nucleus accumbens and relate those changes to cue-induced craving. The goal is to see whether ketamine-dependent modulation of glutamate and the addition of targeted neurofeedback produce clinical benefit or synergistic effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Informed Consent as documented by signature
* In- and outpatients aged 18 to 65 years of all sexes.
* DSM-IV diagnosis of alcohol use disorder (mild - severe).
* Motivation to reduce or stop alcohol use
* Normal level of language comprehension (German or Swiss-German)
* Good physical health with no unstable medical conditions
* Participants of childbearing potential must use an effective and established method of contraception for the entire study duration
* Comply with the study protocol as explained by investigator

Exclusion Criteria:

* History of DSM-IV severe drug dependence other than alcohol (except for caffeine or nicotine) and any opiod use disorder within two months prior to enrolment.
* Hallucinogen and ketamine use 3 months prior to study participation (including regular microdosing).
* Alcohol withdrawal symptoms at any of the treatment visits (V2 and V3) (CIWA-Ar Scale \>9).
* Current or lifetime psychotic disorders
* History of severe substance-induced psychosis
* Current or lifetime bipolar I or II disorders
* Current suicidality
* Previous suicide attempts during the last 2 years
* High risk of adverse emotional and behavioral reactions
* Unmedicated or unstable hypertension
* Severe illness (e. g. myocardial ischemia or arrythmias, severe pulmonary secretions, glaucoma, congestive heart failure or angina, significant renal or hepatic impairment)
* Acute infection (e. g. pulmonary or upper respiratory tract infection)
* Insufficient treated or uncorrected hyperthyroidism
* Severe central nervous system related traumas or disorders (e. g. stroke, cerebral trauma with loss of consciousness over more than 24h, epilepsy)
* During the study, new use or dose changes of already existing concomitant medication without prior informing the investigators.
* Taking medications that are known to modualte uridine diphosphate glucuronosyltransferase-enzyme
* Medication directly affecting glutamate signaling (e. g. anticonvulsant medication)
* Inhibitors of UGT1A9 and 1A10 should be discontinued at least five half-lives prior to the administration of ketamine.
* Monoamine oxidase and aldehyde or alcohol dehydrogenase inhibitors should be discontinued at least 5 half-lives prior to the dose of ketamine.
* Pregnancy or lactation
* Women of childbearing potential with no use of medically accepted contraceptive (e. g. condoms, contraceptive diaphragm, birth control pill, hormone injection, intrauterine device)
* BMI \< 17 or \> 35
* Allergy, hypersensitivity, or other adverse reaction to previous use of ketamine
* Contradictions to magnetic resonance imaging
* Concurrent participation in other clinical study

Where it's running

• Psychiatric University Zurich, University of Zurich
  Zurich, Switzerland Recruiting

Study contacts

• Study coordinator: Marcus Herdener, PD Dr. med.
• Email: marcus.herdener@bli.uzh.ch
• Phone: +41583845810

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for adults with alcohol use disorder

  This study will test whether BrainsWay Deep TMS can reduce heavy drinking in adults with moderate to severe alcohol use disorder compared with a sham procedure.

  Recruiting at 9 sites Brainsway · Tuscaloosa, Alabama and 10 other locations · NCT07216872

• How alcohol changes the social brain during paired interactions

  This study tests whether drinking alcohol changes brain activity and social bonding during conversations between pairs of regular social drinkers aged 21–30.

  Recruiting University of Illinois at Urbana-Champaign · Champaign, Illinois and 1 other locations · NCT07125534

• Tirzepatide's effects on alcohol intake in patients with schizophrenia and alcohol use disorder

  This study is testing if the medication tirzepatide can help people with schizophrenia and alcohol use disorder drink less alcohol over six months.

  Recruiting at 2 sites Phase 2 Psychiatric Centre Rigshospitalet · Aalborg, Denmark and 1 other locations · NCT06939088

• Understanding habits and decision-making in alcohol use disorder

  This study is trying to understand how habits and decision-making affect people with Alcohol Use Disorder compared to those without it.

  Recruiting Technische Universität Dresden · Dresden · NCT06701500

• Investigating how Pavlovian mechanisms influence substance use behaviors

  This study is testing how certain learned responses might affect substance use behaviors in people with moderate to severe substance use disorders compared to healthy individuals.

  Recruiting Technische Universität Dresden · Dresden · NCT06701487

• Imaging Mitochondrial Complex-I and Brain Metabolism in Alcohol Use Disorder

  This study tests whether PET imaging with [18F]BCPP-EF and [18F]FDG can reveal differences in brain energy use between adults with alcohol use disorder and healthy controls, and whether these measures relate to relapse risk.

  Recruiting Early Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07825818

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.